Patents by Inventor Jill A. Livengood
Jill A. Livengood has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10449231Abstract: Embodiments herein report compositions, uses and manufacturing of dengue virus constructs and live attenuated dengue viruses. Some embodiments concern a composition that includes, but is not limited to, a tetravalent dengue virus composition. In certain embodiments, compositions can include constructs of one or more serotypes of dengue virus, such as dengue-1 (DEN-1) virus, dengue-2 (DEN-2) virus, dengue-3 (DEN-3) or dengue-4 (DEN-4) virus constructs. In other embodiments, constructs disclosed herein can be combined in a composition to generate a vaccine against more one or more dengue virus constructs that may or may not be subsequently passaged in mammalian cells.Type: GrantFiled: April 20, 2017Date of Patent: October 22, 2019Assignees: TAKEDA VACCINES, INC., The Government of the United States of America as Represented by the Secretary of the Department of Health and Human ServicesInventors: Dan T. Stinchcomb, Claire Kinney, Richard M. Kinney, Jill A. Livengood
-
Publication number: 20190151433Abstract: Embodiments herein report compositions, methods and uses for dengue-4 (DENV-4) virus constructs. Some embodiments concern a composition that includes, but is not limited to, DENV-4 virus constructs alone or in combination with other constructs, can be used in a vaccine composition to induce an immune response in a subject. In certain embodiments, compositions can include constructs of more than one serotypes of dengue virus, such as dengue-1 virus, dengue-2 virus, or dengue-3 virus in combination with DENV-4 virus constructs disclosed herein. In other embodiments, DENV-4 constructs disclosed herein can be combined in a composition with other flavivirus constructs to generate a vaccine against more than one flavivirus. Other embodiments provide methods and uses for DENV-4 virus constructs in vaccine compositions that when administered to a subject induce an immune response in the subject against DENV-4 that is improved by modified constructs compared to other vaccine compositions.Type: ApplicationFiled: June 1, 2018Publication date: May 23, 2019Inventors: Jill A. Livengood, Claire Kinney, Timothy D. Powell, Dan T. Stinchcomb, Jorge Osorio
-
Publication number: 20190134182Abstract: Embodiments herein relate to compositions of and methods for live attenuated alphaviruses. In certain embodiments, a live, attenuated virus composition includes, but is not limited to, one or more live, attenuated alphaviruses and compositions to reduce inactivation and/or degradation of the live, attenuated alphavirus. In other embodiments, the live, attenuated virus composition may be a vaccine composition. In yet other compositions, a live, attenuated alphavirus composition may include HEPES buffer. In other embodiments, the HEPES buffer may further include a carbohydrate and gelatin and/or a salt.Type: ApplicationFiled: October 12, 2018Publication date: May 9, 2019Inventors: Dan T. Stinchcomb, Jill A. Livengood, Laszlo Varga
-
Patent number: 10137186Abstract: Embodiments herein relate to compositions of and methods for live attenuated alphaviruses. In certain embodiments, a live, attenuated virus composition includes, but is not limited to, one or more live, attenuated alphaviruses and compositions to reduce inactivation and/or degradation of the live, attenuated alphavirus. In other embodiments, the live, attenuated virus composition may be a vaccine composition. In yet other compositions, a live, attenuated alphavirus composition may include HEPES buffer. In other embodiments, the HEPES buffer may further include a carbohydrate and gelatin and/or a salt.Type: GrantFiled: March 13, 2014Date of Patent: November 27, 2018Assignee: Takeda Vaccines, Inc.Inventors: Dan T. Stinchcomb, Jill A. Livengood, Laszlo Varga
-
Publication number: 20180251737Abstract: Embodiments herein report methods, compositions and uses for inducing and/or accelerating viral growth. In certain embodiments, methods, compositions and uses generally related to copolymer compositions for inducing viral growth, reducing lag time and/or increasing viral plaque size. In other embodiments, methods, compositions and uses of copolymer compositions can be for inducing flaviviral growth, reducing lag in growth and/or increasing plaque size.Type: ApplicationFiled: December 28, 2017Publication date: September 6, 2018Inventors: Dan T. Stinchcomb, Jill A. Livengood, O'Neil Wiggan, Richard Kinney, Jorge Osorio
-
Patent number: 10052374Abstract: Embodiments herein report compositions, methods and uses for dengue-4 (DENV-4) virus constructs. Some embodiments concern a composition that includes, but is not limited to, DENV-4 virus constructs alone or in combination with other constructs, can be used in a vaccine composition to induce an immune response in a subject. In certain embodiments, compositions can include constructs of more than one serotypes of dengue virus, such as dengue-1 virus, dengue-2 virus, or dengue-3 virus in combination with DENV-4 virus constructs disclosed herein. In other embodiments, DENV-4 constructs disclosed herein can be combined in a composition with other flavivirus constructs to generate a vaccine against more than one flavivirus. Other embodiments provide methods and uses for DENV-4 virus constructs in vaccine compositions that when administered to a subject induce an immune response in the subject against DENV-4 that is improved by modified constructs compared to other vaccine compositions.Type: GrantFiled: June 28, 2016Date of Patent: August 21, 2018Assignees: Takeda Vaccines, Inc., The United States of America as Represented by the Secretary of the Department of Health and Human ServicesInventors: Jill A. Livengood, Claire Kinney, Timothy D. Powell, Dan T. Stinchcomb, Jorge Osorio
-
Patent number: 9890362Abstract: Embodiments herein report methods, compositions and uses for inducing and/or accelerating viral growth. In certain embodiments, methods, compositions and uses generally relate to copolymer compositions for inducing viral growth, reducing lag time and/or increasing viral plaque size. In other embodiments, methods, compositions and uses of copolymer compositions can be for inducing flaviviral growth, reducing lag in growth and/or increasing plaque size.Type: GrantFiled: September 19, 2014Date of Patent: February 13, 2018Assignee: Takeda Vaccines, Inc.Inventors: Dan T Stinchcomb, Jill A. Livengood, O'Neil Wiggan, Richard Kinney, Jorge Osorio
-
Publication number: 20170290884Abstract: Embodiments herein report compositions, uses and manufacturing of dengue virus constructs and live attenuated dengue viruses. Some embodiments concern a composition that includes, but is not limited to, a tetravalent dengue virus composition. In certain embodiments, compositions can include constructs of one or more serotypes of dengue virus, such as dengue-1 (DEN-1) virus, dengue-2 (DEN-2) virus, dengue-3 (DEN-3) or dengue-4 (DEN-4) virus constructs. In other embodiments, constructs disclosed herein can be combined in a composition to generate a vaccine against more one or more dengue virus constructs that may or may not be subsequently passaged in mammalian cells.Type: ApplicationFiled: April 20, 2017Publication date: October 12, 2017Inventors: Dan T. Stinchcomb, Claire Kinney, Richard M. Kinney, Jill A. Livengood
-
Patent number: 9783579Abstract: Embodiments herein report compositions, uses and manufacturing of dengue virus constructs and live attenuated dengue viruses. Some embodiments concern a composition that includes, but is not limited to, a tetravalent dengue virus composition. In certain embodiments, compositions can include constructs of one or more serotypes of dengue virus, such as dengue-1 (DEN-1) virus, dengue-2 (DEN-2) virus, dengue-3 (DEN-3) or dengue-4 (DEN-4) virus constructs. In other embodiments, constructs disclosed herein can be combined in a composition to generate a vaccine against more one or more dengue virus constructs that may or may not be subsequently passaged in mammalian cells.Type: GrantFiled: March 13, 2014Date of Patent: October 10, 2017Assignees: Takeda Vaccines, Inc., The United States of America as Represented by the Secretary of the Department of Health and Human ServicesInventors: Dan T. Stinchcomb, Claire Kinney, Richard M Kinney, Jill A Livengood
-
Publication number: 20170049874Abstract: Embodiments herein report compositions, methods and uses for dengue-4 (DENV-4) virus constructs. Some embodiments concern a composition that includes, but is not limited to, DENV-4 virus constructs alone or in combination with other constructs, can be used in a vaccine composition to induce an immune response in a subject. In certain embodiments, compositions can include constructs of more than one serotypes of dengue virus, such as dengue-1 virus, dengue-2 virus, or dengue-3 virus in combination with DENV-4 virus constructs disclosed herein. In other embodiments, DENV-4 constructs disclosed herein can be combined in a composition with other flavivirus constructs to generate a vaccine against more than one flavivirus. Other embodiments provide methods and uses for DENV-4 virus constructs in vaccine compositions that when administered to a subject induce an immune response in the subject against DENV-4 that is improved by modified constructs compared to other vaccine compositions.Type: ApplicationFiled: June 28, 2016Publication date: February 23, 2017Inventors: Jill A. Livengood, Claire Kinney, Timothy D. Powell, Dan T. Stinchcomb, Jorge Osorio
-
Patent number: 9408901Abstract: Embodiments herein report compositions, methods and uses for dengue-4 (DENV-4) virus constructs. Some embodiments concern a composition that includes, but is not limited to, DENV-4 virus constructs alone or in combination with other constructs, can be used in a vaccine composition to induce an immune response in a subject. In certain embodiments, compositions can include constructs of more than one serotypes of dengue virus, such as dengue-1 virus, dengue-2 virus, or dengue-3 virus in combination with DENV-4 virus constructs disclosed herein. In other embodiments, DENV-4 constructs disclosed herein can be combined in a composition with other flavivirus constructs to generate a vaccine against more than one flavivirus. Other embodiments provide methods and uses for DENV-4 virus constructs in vaccine compositions that when administered to a subject induce an immune response in the subject against DENV-4 that is improved by modified constructs compared to other vaccine compositions.Type: GrantFiled: November 8, 2013Date of Patent: August 9, 2016Assignees: TAKEDA VACCINES, INC, THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF HEALTH & HUMAN SERVICESInventors: Jill A. Livengood, Claire Y. Huang, Timothy D. Powell, Dan T. Stinchcomb, Jorge Osorio
-
Publication number: 20150010983Abstract: Embodiments herein report methods, compositions and uses for inducing and/or accelerating viral growth. In certain embodiments, methods, compositions and uses generally related to copolymer compositions for inducing viral growth, reducing lag time and/or increasing viral plaque size. In other embodiments, methods, compositions and uses of copolymer compositions can be for inducing flaviviral growth, reducing lag in growth and/or increasing plaque size.Type: ApplicationFiled: September 19, 2014Publication date: January 8, 2015Inventors: Dan T. Stinchcomb, Jill A. Livengood, O'Neil Wiggan, Richard Kinney, Jorge Osorio
-
Patent number: 8871487Abstract: Embodiments herein report methods, compositions and uses for inducing and/or accelerating viral growth. In certain embodiments, methods, compositions and uses generally related to copolymer compositions for inducing viral growth, reducing lag time and/or increasing viral plaque size. In other embodiments, methods, compositions and uses of copolymer compositions can be for inducing flaviviral growth, reducing lag in growth and/or increasing plaque size.Type: GrantFiled: December 4, 2009Date of Patent: October 28, 2014Assignee: Takeda Vaccines, Inc.Inventors: Dan T. Stinchcomb, Jill A. Livengood, O'Neil Wiggan, Richard Kinney, Jorge Osorio
-
Publication number: 20140302088Abstract: Embodiments herein report compositions, uses and manufacturing of dengue virus constructs and live attenuated dengue viruses. Some embodiments concern a composition that includes, but is not limited to, a tetravalent dengue virus composition. In certain embodiments, compositions can include constructs of one or more serotypes of dengue virus, such as dengue-1 (DEN-1) virus, dengue-2 (DEN-2) virus, dengue-3 (DEN-3) or dengue-4 (DEN-4) virus constructs. In other embodiments, constructs disclosed herein can be combined in a composition to generate a vaccine against more one or more dengue virus constructs that may or may not be subsequently passaged in mammalian cells.Type: ApplicationFiled: March 13, 2014Publication date: October 9, 2014Applicants: The Government of the United States of America as Represented by the Secretar, INVIRAGEN, INC.Inventors: Daniel T. Stinchcomb, Claire Y Huang, Richard M Kinney, Jill A Livengood
-
Publication number: 20140271715Abstract: Embodiments herein relate to compositions of and methods for live attenuated alphaviruses. In certain embodiments, a live, attenuated virus composition includes, but is not limited to, one or more live, attenuated alphaviruses and compositions to reduce inactivation and/or degradation of the live, attenuated alphavirus. In other embodiments, the live, attenuated virus composition may be a vaccine composition. In yet other compositions, a live, attenuated alphavirus composition may include HEPES buffer. In other embodiments, the HEPES buffer may further include a carbohydrate and gelatin and/or a salt.Type: ApplicationFiled: March 13, 2014Publication date: September 18, 2014Applicant: INVIRAGEN, INC.Inventors: Daniel T. Stinchcomb, Jill A. Livengood, Lazlo Varga
-
Publication number: 20140134205Abstract: Embodiments herein report compositions, methods and uses for dengue-4 (DENV-4) virus constructs. Some embodiments concern a composition that includes, but is not limited to, DENV-4 virus constructs alone or in combination with other constructs, can be used in a vaccine composition to induce an immune response in a subject. In certain embodiments, compositions can include constructs of more than one serotypes of dengue virus, such as dengue-1 virus, dengue-2 virus, or dengue-3 virus in combination with DENV-4 virus constructs disclosed herein. In other embodiments, DENV-4 constructs disclosed herein can be combined in a composition with other flavivirus constructs to generate a vaccine against more than one flavivirus. Other embodiments provide methods and uses for DENV-4 virus constructs in vaccine compositions that when administered to a subject induce an immune response in the subject against DENV-4 that is improved by modified constructs compared to other vaccine compositions.Type: ApplicationFiled: November 8, 2013Publication date: May 15, 2014Applicants: The Government of the United States of America as Represented by the Secretary of Health & Human S, INVIRAGEN, INC.Inventors: Jill A. Livengood, Claire Y. Huang, Timothy D. Powell, Dan T. Stinchcomb, Jorge Osorio
-
Publication number: 20100144015Abstract: Embodiments herein report methods, compositions and uses for inducing and/or accelerating viral growth. In certain embodiments, methods, compositions and uses generally related to copolymer compositions for inducing viral growth, reducing lag time and/or increasing viral plaque size. In other embodiments, methods, compositions and uses of copolymer compositions can be for inducing flaviviral growth, reducing lag in growth and/or increasing plaque size.Type: ApplicationFiled: December 4, 2009Publication date: June 10, 2010Inventors: Dan T. Stinchcomb, Jill A. Livengood, O'Neil Wiggan, Richard Kinney, Jorge Osorio